Category Archives: HIV care & treatment

Project Inform Applauds California Lawmakers for Supporting Hepatitis C and HIV Services in the 2015-16 State Budget

June 25, 2015, San Francisco, CA – Project Inform, the managing member of the California Hepatitis Alliance and a member of the California HIV Alliance, applauds the California Legislature and Governor Brown’s support for hepatitis C and HIV services in the Fiscal Year 2015-2016 budget. The…Read More

Early treatment for HIV: Making good on the promise of care and prevention

post_start

Long before the results of the START study were recently published, showing a 53% reduction in AIDS and non-AIDS conditions and deaths in people starting treatment immediately compared with those who waited until CD4s fell below 350, the San Francisco Department of Public Health and Project…Read More

Major study confirms benefit of early HIV treatment start

nihhhsnews

A 4,500+ person randomized clinical trial has confirmed that starting antiretroviral (ARV) therapy at higher CD4 counts reduces the risk of AIDS and non-AIDS conditions by 53%. The study, called Strategic Timing of AntiRetroviral Treatment (START), and which started in March 2011, enrolled 4,685 people around…Read More

Covered California staff recommends capping specialty prescription drug costs

post_coveredca

Project Inform applauds the recent recommendation by Covered California staff to cap specialty prescription drug costs at $250 per drug per month for 2016 Covered California Silver, Gold and Platinum level plans. The recommendation will be made Thursday, May 21 at the Covered California Board meeting….Read More

VIDEO: How San Francisco plans to ‘get to zero’ new infections of HIV

post_G20

Project Inform is on the steering committee for this effort to bring new HIV infections to zero, along with zero deaths and zero stigma. Watch this PBS video for more information.

CROI2015: New “Kick and Kill” HIV cure drug (TLR7 agonist) from Gilead shows promise

post_croi2015

A new type of drug, called a toll-like receptor 7 (TLR7) agonist, was able to activate HIV-infected CD4 cells from HIV-positive donors on antiretroviral therapy (ART), leading to the release and replication of virus, according to a presentation at the 2015 Conference on Retroviruses and Opportunistic…Read More

CROI2015: Financial incentives don’t increase case linkage or viral suppression

post_croi2015

A large study presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle found that offering gift cards to people to reward them for getting into HIV care after testing positive or for getting their viral loads suppressed doesn’t work better than the…Read More